Evidence map›Paper›PMID 33362780›Full record

ArticleFrontiers in immunology2020

IL-2-Agonist-Induced IFN-γ Exacerbates Systemic Anaphylaxis in Food Allergen-Sensitized Mice.

Christopher W M Link, Christina N Rau, Christopher C Udoye, Mohab Ragab, Rabia Ü Korkmaz, Sara Comdühr, Ann-Katrin Clauder, Timo Lindemann, Britta Frehse, Katharina Hofmann and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Single-dose AAV vector gene immunotherapy to treat food allergy.Molecular therapy. Methods & clinical development · 2022
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Christopher W M LinkInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Christina N RauInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Christopher C UdoyeInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Mohab RagabInstitute of Nutritional Medicine, University of Lübeck, Lübeck, Germany.
Rabia Ü KorkmazInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Sara ComdührInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Ann-Katrin ClauderInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Timo LindemannInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Britta FrehseInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Katharina HofmannInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Larissa N AlmeidaInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Yves LaumonnierInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Asmaa El BeidaqInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
Fred D FinkelmanDivision of Allergy, Immunology and Rheumatology, Department of Internal Medicine, University of Cincinnati College of Medicine and the Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Rudolf A ManzInstitute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany.
University of Lübeck · DEUniversity of Cincinnati · US

Funding

Rapid, safe suppression of IgE-mediated disease with monovalent anti-ceRIa mAbR01AI145991 · NIAID · UNIVERSITY OF CINCINNATI · PI FINKELMAN, FRED DOUGLASS, KHODOUN, MARAT · 2019 to 2023
$2.6M
Wimpy antibody isotypes protect against antibody-mediated diseaseR01AI130103 · NIAID · UNIVERSITY OF CINCINNATI · PI FINKELMAN, FRED DOUGLASS · 2017 to 2021
$1.8M
Suppression of IgE-Mediated Disease by Polyclonal Rapid DesensitizationR01AI113162 · NIAID · UNIVERSITY OF CINCINNATI · PI FINKELMAN, FRED DOUGLASS · 2014 to 2017
$1.6M
NIAID NIH HHS R01 AI113162NIAID NIH HHS R01 AI130103NIAID NIH HHS R01 AI145991
6 · The paper itself

Abstract

Food allergies are common, costly and potentially life-threatening disorders. They are driven by Th2, but inhibited by Th1 reactions. There is also evidence indicating that IL-2 agonist treatment inhibits allergic sensitization through expansion of regulatory T cells. Here, we tested the impact of an IL-2 agonist in a novel model for food allergy to hen´s egg in mice sensitized without artificial adjuvants. Prophylactic IL-2 agonist treatment expanded Treg populations and inhibited allergen-specific sensitization. However, IL-2 agonist treatment of already sensitized mice increased mast cell responses and allergic anaphylaxis upon allergen re-challenge. These effects depended on allergen-specific IgE and were mediated through IFN-γ, as shown by IgE transfer and blockade of IFN-γ with monoclonal antibodies. These results suggest that although shifting the allergic reaction toward a Treg/Th1 response inhibits allergic sensitization, the prototypic Th1 cytokine IFN-γ promotes mast cell activation and allergen-induced anaphylaxis in individuals that are already IgE-sensitized. Hence, while a Th1 response can prevent the development of food allergy, IFN-γ has the ability to exacerbate already established food allergy.

Indexed as

AllergensAnaphylaxisAnimalsChickensCytokinesDisease Models, AnimalEgg WhiteFemaleFoodFood HypersensitivityImmunizationImmunoglobulin EInterferon-gammaInterleukin-2MiceAllergensCytokinesImmunoglobulin EInterferon-gammaInterleukin-2anaphylaxisfood allergyIFN-γIL-2murine model

Identifiers

PMID33362780
PMCPMC7759672
OpenAlexW3113114371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.